EUVIMEDEUVIMED entdecken
Crossref

Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival

Daniel Solomon, Ashley L Deeb, Kamal Tarabine, Yue Xie, Emanuele Mazzola, Lei Zhao, Mark M Hammer, Michael T Jaklitsch, Scott J Swanson, Raphael Bueno, Jon O Wee

The Journal of Thoracic and Cardiovascular Surgery · 2024

DOI: 10.1016/j.jtcvs.2023.11.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Daniel Solomon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, Mass. Electronic address: daniel.s985@gmail.com. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Neoadjuvant Therapy, Esophagectomy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The prognostic value of tumor regression scores (TRS) in patients with esophageal adenocarcinoma (EAC) who underwent neoadjuvant chemoradiation remains unclear. We sought to investigate the prognostic value of pathologic and metabolic treatment response among EAC patients undergoing neoadjuvant chemoradiation. METHODS: Patients who underwent esophagectomy for EAC after neoadjuvant CROSS protocol between 2016 and 2020 were evaluated. TRS was grouped according to the modified Ryan score; metabolic response, according to the PERCIST criteria. Variables from endoscopic ultrasound, endoscopic biopsies, and positron emission tomography (primary and regional lymph node standardized uptake values [SUVs]) were collected. RESULTS: The study population comprised 277 patients. A TRS of 0 (complete response) was identified in 66 patients (23.8%). Seventy-eight patients (28.1%) had TRS 1 (partial response), 97 (35%) had TRS 2 (poor response), and 36 (13%) had TRS 3 (no response). On survival analysis for overall survival (OS), patients with TRS 0 had longer survival compared to those with TRS 1, 2, or 3 (P = .010, P < .001, and P = .005, respectively). On multivariable logistic regression, the presence of signet ring cell features on endoscopic biopsy (odds ratio [OR], 7.54; P = .012) and greater SUV uptake at regional lymph nodes (OR, 1.42; P = .007) were significantly associated with residual tumor at pathology (TRS 1, 2, or 3). On multivariate Cox regression for predictors of OS, higher SUVmax at the most metabolically active nodal station (hazard ratio [HR], 1.08; P = .005) was independently associated with decreased OS, whereas pathologic complete response (HR, 0.61; P = .021) was independently associated with higher OS. CONCLUSIONS: Patients with pathologic complete response had prolonged OS, whereas no difference in survival was detected among other TRS categories. At initial staging, the presence of signet ring cells and greater SUV uptake at regional lymph nodes predicted residual disease at pathology and shorter OS, suggesting the need for new treatment strategies for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAdenocarcinomaNeoadjuvant TherapyEsophagectomyHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeChemoradiotherapy, AdjuvantPositron-Emission Tomography

Stichwörter der Autor:innen

chemoradiationesophageal adenocarcinomametabolic responseneoadjuvantpathologic response

Autor:innen und Institutionen

  • Division of Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, Mass. Electronic address: daniel.s985@gmail.com.
  • Division of Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, Mass.
  • Department of Radiology, Brigham and Women's Hospital, Boston, Mass.
  • Department of Data Sciences, Dana Farber Cancer Institute, Boston, Mass.
  • Department of Pathology, Brigham and Women's Hospital, Boston, Mass.

Zitieren

APA

Solomon, D., Deeb, A. L., Tarabine, K., Xie, Y., Mazzola, E., Zhao, L., Hammer, M. M., Jaklitsch, M. T., Swanson, S. J., Bueno, R., & Wee, J. O. (2024). Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2023.11.015

Vancouver

Solomon D, Deeb AL, Tarabine K, Xie Y, Mazzola E, Zhao L, et al. Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival. The Journal of Thoracic and Cardiovascular Surgery. 2024. doi:10.1016/j.jtcvs.2023.11.015

BibTeX
@article{Solomon2024,
  author = {Solomon, Daniel and Deeb, Ashley L and Tarabine, Kamal and Xie, Yue and Mazzola, Emanuele and Zhao, Lei and Hammer, Mark M and Jaklitsch, Michael T and Swanson, Scott J and Bueno, Raphael and Wee, Jon O},
  title = {Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  doi = {10.1016/j.jtcvs.2023.11.015}
}
Kostenlos starten →